Martin Dietrich, MD, PhD

The Clinical Importance of HER2 Testing in mNSCLC

September 3rd 2025

Dr Dietrich on the FDA Approval of Zongertinib for HER2 TKD–Mutated Nonsquamous NSCLC

August 8th 2025

Martin Dietrich, MD, PhD, discusses the FDA accelerated approval of zongertinib for HER2-mutated or metastatic nonsquamous NSCLC.

Guideline Updates and Trial Data Solidify the Role of HER2/MET IHC Testing in NSCLC: With Martin F. Dietrich, MD, PhD

August 4th 2025

Dr Dietrich discusses the rationale for testing for HER2 and MET mutations in patients with NSCLC, as well as best practices for implementing this testing.

Dr Dietrich on the Efficacy and Safety of Taletrectinib in ROS1+ NSCLC

July 31st 2025

Martin F. Dietrich, MD, PhD, discusses the efficacy and safety profiles of taletrectinib for the management of ROS1-positive non–small cell lung cancer.

How the Mechanisms of KRAS(ON) Inhibitors Differ From KRAS(OFF) Inhibitors

July 25th 2025

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss how KRAS(ON) inhibitors differ in mechanism from KRAS(OFF) inhibitors.

The Current and Evolving Role of KRAS G12C and Pan-KRAS Inhibitors in Metastatic PDAC

July 24th 2025

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss the evolving role of KRAS G12C and pan-KRAS inhibitors in pancreatic cancer.

The Prevalence of RAS Mutations in Metastatic PDAC

July 10th 2025

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss the prevalence of RAS mutations in pancreatic ductal adenocarcinoma.

Explaining the Continued Interest in RAS Inhibition for PDAC

June 26th 2025

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, detail the continued interest in RAS inhibition for pancreatic ductal adenocarcinoma.

Final Thoughts on the Treatment of EGFR-Mutant NSCLC: Balancing Safety and Efficacy, and the Importance of Incorporating Supportive Care Strategies

May 23rd 2025

Panelists discuss how implementing the new standard of combination therapies requires thorough patient education, prophylactic management of toxicities, and multidisciplinary support to optimize outcomes for patients with EGFR-mutant lung cancer.

The Future of Biomarkers in EGFR-Mutant NSCLC: Sequencing Strategies and Optimizing Patient Time on Treatment

May 23rd 2025

Panelists discuss how optimizing treatment duration, using local therapy for oligometastatic disease, and understanding the limitations of current biomarkers are important considerations in developing effective sequencing strategies for EGFR-mutant lung cancer.

Treatment Options in the Second-Line for CNS Protection In EGFR-Mutant NSCLC

May 23rd 2025

Panelists discuss how central nervous system (CNS) progression presents unique challenges in treatment decision-making, highlighting the importance of brain imaging surveillance and considering approaches that maintain CNS disease control while addressing systemic progression.

The Impact of Frontline Treatment Selection on Second-line Therapy for EGFR-mutant NSCLC

May 16th 2025

Panelists discuss how many patients never receive second-line therapy, emphasizing the critical importance of selecting the optimal first-line treatment and monitoring patients closely to identify progression early.

Disease Reassessment at First Progression and Treatment Options for Resistance Mechanisms in EGFR-mutant NSCLC

May 16th 2025

Panelists discuss how subsequent therapy after initial disease progression should consider patient symptomatology, biomarker testing through tissue or liquid biopsies, and potential treatment options including MET-targeted approaches or chemotherapy combinations.

The Importance of Quality of Life in Treatment Decision-Making for EGFR-Mutant NSCLC

May 9th 2025

Panelists discuss how quality of life considerations, including prophylactic medications to prevent dermatologic toxicities and infusion-related reactions, are crucial when implementing EGFR-targeted therapies, especially the MARIPOSA regimen.

Analyzing the MARIPOSA Overall Survival Data in the Frontline Treatment of EGFR-Mutant NSCLC

May 9th 2025

Panelists discuss how the overall survival benefit from the MARIPOSA regimen (amivantamab plus lazertinib) with a hazard ratio of 0.75 and projected survival improvement exceeding 1 year represents a significant advancement that must be weighed against toxicity concerns.

Presenting the Treatment Options in EGFR-Mutant NSCLC: Weighing the Data and Incorporating the Patient Perspective

April 28th 2025

Panelists discuss how conversations with patients about treatment options have become more complex and nuanced, requiring thorough explanation of efficacy data and adverse effects while adapting to each patient’s level of understanding and involvement.

Combination Therapy: A New Frontline Standard in the Treatment of EGFR-Mutant NSCLC

April 28th 2025

Panelists discuss how the treatment landscape for EGFR-mutant non–small cell lung cancer has evolved with new combination therapies like osimertinib plus chemotherapy (FLAURA2) and amivantamab plus lazertinib (MARIPOSA) challenging osimertinib monotherapy as the standard of care.

Unmet Needs in LCNEC

January 13th 2025

Panelists discuss what they would like to see in future trials to address the unmet needs and challenges in treating patients diagnosed with lung large cell neuroendocrine carcinoma (LCNEC).

Potential Next-Generation Therapies for Lung LCNEC

January 6th 2025

Panelists discuss any upcoming trials on the horizon that they are excited about in the context of lung large cell neuroendocrine carcinoma (LCNEC) treatment.

Insights Into Ongoing Investigational Studies in Lung LCNEC

January 6th 2025

Panelists discuss ongoing lung large cell neuroendocrine carcinoma (LCNEC) trials involving both familiar and novel agents, including phase 2 durvalumab + EP (1L), phase 2 LCNEC-ALPINE atezolizumab + EP (1L), phase 1/2 SKYBRIDGE PT217 DLL3/CD47 bispecific antibody (2L+), and phase 1 LB2102 DLL2-directed CAR T (2L+).